Anavex Life Sciences Corp (AVXL)

[F1ash]

...and if you think a 20 year veteran of the FDA is working for a company that is totally ignorant of basic protocols as you seem to imply, there is a cognitive disconnect somewhere

Did patients drop out from the trial during the first 52 weeks?

Here is a graph from a data presentation just last month. I believe it's their most current one.


The only possible way investors can judge how A2-73 is performing is through data Anavex presents correct?

So I ask you to search their presentation and tell me how this graph represents the dropout's scores?






Slide 26

http://wsw.com/webcast/jeff105/avxl/


Perhaps I missed it somewhere. Do they not realize they have to include that information to enable investors to accurately assess it, or did they just leave it out intentionally? If they left it off intentionally, why?

The nicest explanation I can come up with is whoever is putting there presentations together is just not very good at their job. The other two explanations are not very comforting.

"The following data represents all(in italics) evaluable patients. ".

So simple question. What is the number of patients represented in that graph on slide 26? It's a basic reasonable question right?



I'm not here to bash this company. I actually hope some of you help me find the answers to questions that make me leery to invest here again.

Are my questions unreasonable? If so why?